We have developed a functional screen in yeast to identify ligands for receptor tyrosine kinases. Using this method, we cloned two Xenopus genes that activate the fibroblast growth factor (FGF) receptor. These encode novel secreted proteins, designated FRLl and FRLP, distantly related to the epidermal growth factor and angiogeniruribonuclease families, respectively. Both genes activate the FGF receptor in Xenopus oocytes as well as in yeast. Overexpression induces mesoderm and neural-specific genes in Xenopus explants; induction is blocked by a dominant negative inhibitor of the FGF receptor. FRLl is broadly expressed during gastrulation and neurulation, while FRL2 is expressed principally in the axial mesoderm and brain at later stages. Our results indicate that despite their lack of similarity with FGF, FRLl and FRL2 are ligands for the FGF receptor that play distinct roles in development.
In the ten plasmids that activated the FGF receptor, there were six unique sequences (Table 1) . These genes encode two putative secreted proteins (FRLI and FRL2), one protease (XT2), two RNA-binding proteins (EGl and EG3), and one novel protein (EG4) lacking a signal sequence. FRLl and XT2 were isolated from the XTC library, and the others are from the egg library. Genes related to the traditional FGF gene family were not isolated in this screen.
FRL-2 FRL-P glucose galactose were streaked, and the colonies were transferred to two membranes and cultured on a glucose-containing or a galactose-containing plate. The membraneswere analyzed by colony immunoblotting method with anti-phosphotyrosine antibody.
Of particular interest were the two genes FRL7 and FRLP, which encoded polypeptides with putative signal sequences. Figure 2 shows that phosphotyrosine levels increase dramatically in yeast strains expressing the FGF receptor together with either FRLl or FRL2. FRLl is distantly related to cripto, which is an EGF family member identified in the mouse and human ( Figure 3A ; Ciccodicola et al., 1989; Dono et al., 1993) . Though the predicted amino acid sequence identity is very low (24%) compared with human and mouse cripto, the EGF motif is completely conserved. FRLP encodes a protein weakly homologous to the angiogeninlribonuclease superfamily ( Figure 36 ; Beintema et al., 1988) . The identity again was very low: 21% to both bovine angiogenin (Maes et al., 1988) and bovine pancreatic ribonuclease A (Smyth et al., 1963; Carsana et al., 1988) , and 26% to the bullfrog ribonucleasel sialic acid-binding lectin (Titani et al., 1987) . Phylogenetic analysis of these genes shows that FRLP does not seem to belong to either the angiogenin or the ribonuclease branches ( Figure 3D ).
Both FRLl and FRLP have hydrophobic regions at the C-terminus; the N-terminal hydrophobic domain probably is the signal sequence ( Figure 3C ). These proteins could be anchored to the cell membrane by their C-termini. To test this possibility, we expressed these genes and the C-terminal deletion mutants of these genes in Xenopus oocytes and found that the deletion mutants were secreted into the media, whereas the full-length gene products were not (data not shown). This suggests that FRLl and FRL2 retain an association with membranes or vesicles and that the C-terminal regions are required for this association.
The XT2 sequence was found to be similar to human cathepsin L, sharing 58% amino acid identity in the region we sequenced (90 out of 155 amino acids; data not shown; Joseph et al., 1988; Gal and Gottesman, 1988) . EGl was previously identified in Xenopus as a heterogeneous ribonucleoprotein (Kay et al., 1990) . EG3 has an RNA recognition motif found in many RNA-binding proteins (data not shown; Kim and Baker, 1993) . EG4 encodes a novel 96 kDa protein. Recently, a gene similar to EG4 was found by the complete sequencing of the chromosome III in Caenorhabditis elegans; it was designated Rl OE12.1 (39% identity), but its function is unknown (Wilson et al., 1994) . No putative signal sequence was found in this gene (data not shown). with the vector alone. Binding was completely competed by unlabeled FGF. These results indicate that FRL2 binds to the extracellular domain of the FGF receptor, and that FGF and FRL2 share a common binding site on the FGF receptor. We were unable to coprecipitate FRLl with the same binding assay (data not shown).
FRLl and FRL2 Induce Mesoderm through the FGF Receptor Signaling Pathway in Animal Cap Explants from Xenopus Embryos
It is known that exposure to FGF and other related growth factors induces mesoderm in animal caps isolated from Xenopus embryos (Kimelman and Kirschner, 1987; Slack et al., 1987; lsaacs et al., 1992) . We tested whether FRLl and FRL2 might also be capable of inducing mesoderm through activation of the FGF receptor. We injected mRNA encoding FRLl and FRL2 into both blastomeres of 2-cell embryos, isolated the animal caps at stage 8, and incubated them until sibling embryos had reached stage 20. Uninjected caps rounded up, giving the uninduced phenotype of epidermis. Animal caps injected with FRLI or FRLP RNAs exhibited striking morphological changes, with FRLl-injected animal caps elongating more than FRL2-injected animal caps ( Figure 6A ). Both showed more extreme morphological responses than animal caps treated with FGF.
To demonstrate that these animal caps had responded to the ligands by changing the state of differentiation, we assayed them by reverse transcription-polymerase chain reaction (RT-PCR) for expression of muscle actin, which is a mesodermal marker, and neural cell adhesion molecule (N-CAM), a neural marker. As shown in Figure 6B , FRL2 induced muscle actin, but did not induce N-CAM. By contrast, FRLl induced both muscle actin and N-CAM at higher doses of injected RNA (5 ng), but at lower doses (1 ng), FRLl induced only N-CAM. At 5 ng, FRL2 RNA was toxic.
We tested the dependence of FRLl and FRL2 activities on the FGF receptor by coexpressing a dominant negative FGF receptor (XFD; Amaya et al., 1991) . XFD is a dominant negative mutant in which almost all the cytoplasmic domain of the receptor is deleted; it is thought to inhibit the FGF receptor by forming a heterodimerwith the endog- enous FGF receptor. As a control in these experiments, we used HAV@, which is a mutated form of XFD with a deletion of three amino acids in its extracellular domain; HAV@ does not inhibit the activation of the FGF receptor by FGF (Byers et al., 1992; Amaya et al., 1993) . mRNA encoding XFD or HAV@ mutants was coexpressed with FRLl or FRL2 in animal caps, and the induction of muscle actin and N-CAM genes was assayed by RT-PCR. Surprisingly, as shown in Figure 6B , the induction of muscle actin by FRLl was inhibited by both XFD and HAV@. Similarly to FGF, the induction by FRL2 was inhibited by XFD but not by HAV@. Inhibition of both FRLl and FRL2 by XFD indicates that the activation of the FGF receptor is required for the function of FRLl and FRL2. This strongly suggests that FRLl and FRL2 bind to the extracellular domain of the dominant negative receptor and form a het- erodimer with the full-length receptor to inhibit the receptor activation. The differences between the response of XFD and HAV@ to FFiLl and both FRLP and FGF suggest possible differences in the interactions of these ligands with the extracellular domain of the FGF receptor.
FRLI and FRL2 Can Act in a Non-Cell-Autonomous
Manner To test whether FRLl and FRL2 act as intercellular signaling molecules, we have employed a paracrine signaling assay developed by Lustig and Kirschner (1995; Figure  7A ). In this assay, mRNA encoding FRLl or FRL2 was injected into oocytes and cultured for 1 day, after which animal caps from stage 8 embryos were grafted onto the oocytes. The animal caps were harvested when the sibling embryos reached stage 25 and were analyzed by RT-PCR. If the proteins act intercellularly, the proteins produced in oocytes are expected to activate the receptors of the grafted tissues, resulting in the induction of the muscle actin, N-CAM genes, or both. As shown in Figure 78 , both FRLl and FRL2 expressed in oocytes induced muscle actin and N-CAM in the animal caps. This induction was comparable to that for whole embryos when normalized for elongation factor 1 a (EFl a). This result strongly suggests that FRLl and FRL2 can act in a non-cell-autonomous manner.
Tail-like Appendages from the Ectopic Expression of FRL1
To investigate the activity of FRLl and FRLP in embryogenesis, mRNAs encoding these proteins were in- Stage 10 embryos were dissected into the dorsal half (Dr) and the ventral half (Vn), or into the vegetal half including the marginal zone (Vg) and the animal half (An), and RNA was isolated from these tissues or from stage 10 embryos (Em). The expression of the FRLl gene was assayed by RT-PCR. goosecoid (gsc) is known to be expressed in the dorsal marginal zone (Cho et al., 1991) . EFlu is a ubquitously expressed control (Krieg et al., 1989 jetted into 2-cell embryos, and the phenotype was observed. As shown in Figure 6C , a common phenotype in both FRL7-injected and FRL2-injected embryos was reduced anterior head morphology. Embryos without eyes, cement gland, or both were often found (11 out of 30 embryos injected with 1 ng of FRL7 and 11 out of 32 embryos injected with FRLP RNA at 2-cell stage). In addition, FRL7 induced tail-like appendages (11 out of 30 embryos). At tadpole stage, a fin and melanocytes were formed, but neither notochord nor somites could be identified in these appendages by immunohistochemistry (data not shown). The FRLP-injected embryos showed severe gastrulation defects as well as head defects. The head defect phenotype suggests that ectopic expression of FRLl and FRL2 might cause posteriorization of anterior tissue, or loss of anteriorization.
The Temporal and Spatial Expression Pattern of FRLI and FRLP in Xenopus Embryo
The temporal expression patterns of FRL7 and FRL2 were mapped with RT-PCR, using ornitihine decarboxylase as an internal standard. As shown in Figure 8A , both FRL7 and FRLP mRNAs were of low abundance maternally, but were clearly detected by stage 10. The FRLP transcript gradually increased during embryogenesis through stage 38, whereas the FRL7 transcript was detectable only during gastrula stages and disappeared rapidly at early neurula stage.
The spatial distribution of FRL7 expression was mapped with whole-mount in situ hybridization on gastrula stage embryos. Expression was detected throuighout the embryo at gastrula stage (data not shown). When we dissected embryos into dorsal and ventral or animal and vegetal pieces at gastrula stage, we found broad and uniform expression of FRL7 by RT-PCR, confirmiing the lack of localization by in situ hybridization ( Figure 8B ). As a control, we found goosecoid expression limited to the dorsal lip, and EFla uniformly expressed. In situ hybridization of FRLP at tailbud stage shows expression in somites, otic vesicles, brain, eyes, cement gland, and visceral arches, suggesting that FRl.2 might be involved in the development of these tissues ( Figure 8C ).
Discussion
There are several transmembrane tyrosine kinase receptors known to be expressed at gastrula and neurula stage in Xenopus embryos, which suggests that several undiscovered ligands might be present that would play a role in early patterning and tissue differentiation
To identify these molecules, we have developed a functional assay in yeast for ligands for tyrosine kinase receptors. Initially we demonstrated that we can reproduce the activation of the kinase by coexpression of the receptor and ligand by use of the FGF receptor and FGF2. We tested this assay on two Xenopus cDNA libraries and identified two novel secreted proteins, FRLl and FRLP, that activate the FGF receptor in the yeast assay. Surprisingly, lthese ligands are not members of the homologous class of FGF ligands and therefore constitute putative novel extracellular activators of the FGF receptor.
Several lines of evidence suggest that FRLl and FRLP can activate the FGF receptor extracellularly, although proof that the FGF receptor is the appropriat'e receptor for these or any of the FGF family of ligands is slill inferential. In addition to the yeast assay, both of these lllgands stimulate calcium release in Xenopus oocytes in the presence of a functional FGF receptor. The paracrine assay shown in Figure 7 shows that both FRLI and FRL2 can be expressed in one cell (the oocyte) and act on another (animal caps); hence, FRLl and FRL2 can act in a non-cellautonomous manner.
In the cake of FRL2, we were able to demonstrate that the ligand binds to the extracellular domain of the FGF receptor and that this binding can be competed by FGFP. Our inability to demonstrate this interaction with FRLl could be due to weaker affinity or lack of activity of the FRLl in the presence of the detergents needed to solubilize it.
Further evidence that FRLl and FRL2 acts through the FGF receptor has come from induction assays in frog embryos. Both of these molecules gave potent and interesting biological effects (discussed below), and these effects, which include expression of muscle actin and morphological changes, were completely blocked by c'oexpression of the dominant negative mutant of the FGF receptor, XFD. Formally, these experiments show that the biological effects of FRLl and FRL2 require FGF signaling, but do not prove that these ligands act directly on the FGF pathway. FRLl and FRLP might stimulate production Nor secretion of endogenous FGF molecules in oocytes or anirnal caps, or they might stimulate both activities. Indeed, it is known thatXFD inhibitsthe mesoderm induction byactivin, which does not interact with the FGF receptor (LaBonne and Whitman, 1994; Cornell and Kimelman, 1994) . However, one unusual experimental result suggests that this is not the case for FRLl. Its ability to induce muscle actin was inhibited, and its ability to induce N-CAM was partially inhibited not only by XFD, but also by a mutant form of the dominant negative inhibitor, HAV@, that does not inhibit FGFfunction (Byers et al., 1992 , Amaya et al., 1993 . This indicates that FRLl does not function through endogenous FGF and may suggest that FRLl interacts with different binding determinants in the FGF receptor than does FRL2 or FGF. Taken together, these data suggest a direct interaction for both FRLl and FRL2 with the FGF receptor but provide strict proof only for FRLP, where direct and FGF-competable binding with the extracellular domain can be demonstrated.
Finding a new member of the FGF family of ligands would be interesting but not surprising. Finding two novel putative ligands with no homology to the FGF familly members is more unusual, since in general, receptor tyrosine kinases have been thought to interact with specific ligand family members. However, FGF receptor family members differ in their extracellular domains, which could be the basis of differences in receptor binding. Indeed, we have found that the FGF receptor 4 from Xenopus can be activated in the yeast assay with FGFP but not with FFlLl and FRL2 (N.K., unpublished data) , while the FGF receptor 1 can be activated by all three ligands. Interactions of a receptor with more than one ligand family are not unprecedented. For example, the insulin-like growth factor (IGF)-II receptor interacts not only with IGF-II but also with mannose8-phosphate, and IGF-II also interacts with the IGF-I receptor (Morgan et al., 1987; Rechler et al., 1980) . The Nature of FRLI and FRLP and Their Role in Development FRLl contains an EGF motif, with only 24% identity to mouse cripto. In the mouse embryo, cripto is expressed in the primitive streak and mesodermal cells, and llater in the heart (Dono et al., 1993) , suggesting that cripto might be involved in mesoderm formation. In Xenopui, FRLl is expressed throughout gastrulation and early neurulation, a period of about 4 or 5 hr, and is not localized. FRLl could be regulated posttransriptionally or posttranslationally.
FRLl shows different inductive effects compared with those of FGFor FRLP. A high dose of FRL7 mRNA induced both muscle actin and N-CAM, while a lower dose induced only N-CAM, but not muscle actin. Hence, FRLl can induce neural tissue without inducing appreciable mesoderm or at least muscle in this assay. Though other mesoderm inducers, such as activin, can also induce rneural tissues, this is thought to be an indirect induction meldiated by the dorsal mesoderm induced by activin.
FRL2 shows no homology to typical FGF family members but is distantly related to the ribonuclease/angialgenin family (identities of 21%-26%).
These molecules share conserved cysteine positions and a conserved histidine bounded by valine and phenylalanine in the C-terminus. Angiogenin has strong angiogenic activity, which is also true of FGF (Folkman and Klagsburn, 1987; Risau, 1990) . There is no known receptor for angiogenin, and it is tempting to speculate that angiogenin, like FRLP, might activate a member of the FGF family of receptors, rationalizing why it is effective as an angiogenic agent. FM2 mRNA was detected at gastrula stage and gradually increased through tadpole stage. It is expressed broadly in somites, nervous system, eyes, cement gland, and visceral arches, where the FGF receptors 1 and 4 are expressed (Brandli and Kirschner, 1995) .
The Yeast Assay for Tyrosine Kinase Function In the initial studies of the FGF receptor and basic FGF, we found that the receptor was activated only if FGF possessed a signal sequence (ssFGF). We did not determine cytological localization of the receptor or the ligand. However, ssFGF expressed in yeast was not detected in the medium by immunoblotting with anti-FGF antibody, suggesting that the FGF receptor might be activated in intracellular compartments.
This property made the assay strictly cell autonomous. Theoretically, there is no reason why ligands and receptors could not meet in intracellular vesicles and signal in the cytoplasm. In mammalian cells, the v-sis oncogene, a dimer of PDGF 0 chains, has been shown to transform cells without secretion by activating the PDGF receptor in intracellular compartments (Keating and Williams, 1988; Westermark and Heldin, 1991) . The receptor may be activated by FGF in yeast and higher organisms in the similar manner, where activation of the receptor could occur by an encounter with the ligand in the endoplasmic reticulum, Golgi, or other vesicular compartment.
To our surprise, the initial screen for FGF ligands did not produce typical FGF ligands, despite the demonstration that FGFP is active in the assay. Part of that reason may be that the level of maternal mRNA encoding FGF is greatly reduced after oocyte maturation (Kimelman and Kirschner, 1989) , and the other FGF forms may be quite rare. It might be that the signal sequence of these FGFs might not be functional in yeast. Finally, it could be that owing to glycosylation differences, FGFs synthesized in yeast may have low affinities for the receptor. Three other proteins activated the receptor. There are avariety of ways a protease and RNA binding-proteins might affect the level of expression or its function.
It has become increasingly clear that several signaling systems operate in the early embryo to specify the pattern and differentiation of tissues. The existence of large families of receptors and ligands is not likely to reflect simply redundancy but different signals for different processes. In general, it is not possible to identify which ligand and receptor interact in vivo. The discovery of novel FGF receptor ligands along with the multiplicity of FGF-type receptors intensifies this issue. The results of this investigation suggest that receptors may be even more promiscuous than simply operating within a single family of ligands. To identify these ligands, screening by structural homology might need to be augmented by independent screens based on functional assays.
Experimental Procedures
Yeast Strain and Plasmids
The yeast (S. cerevisiae) strain used in this study was PSY315 (Mata, /euZ-3.122, ura3-52, his3-d200, /ysZ-802).
The vector plasmids pTS210 and pTS249 carry URA3 and LEUP, respectively, and both carrythe CfN4, GAL1 promoter and ACT7 terminator (gifts from Dr. T. Stearns, Stanford University).
pKNA1 is the same as pTS249, except that the GAL promoter is replaced with ACT7 promoter. The promoter of ACT1 (Gallwitz et al., 1981) was cloned by PCR using yeast genomic DNA as a template. The length of the frag ment is 678 bp.
Two plasmids for expression of Xenopus FGF2 in yeast were constructed: one plasmid was constructed by cloning FGF2 into pTS210 (pFGF), and the other plasmid is identical to the first one, except that a signal sequence of S. cerevisiae SUC2 (Carlson et al., 1983 ) was inserted at the initiation codon of the FGF2 gene (pssFGF).
For FGF receptor expression, the Xenopus FGF receptor 1 gene (Musci et al., 1990) was subcloned into pTS249 and pKNA1 (pG-FGFR and PA-FGFR, respectively).
The full-length construct XFR and the dominant negative construct XFD of the FGF receptor have been described by Amaya et al. (1991) . The deleted mutant construct HAV@ has been described by Amaya et al. (1993) .
The vector plasmid pCS2+ (Turner and Weintraub, 1994) was used for in vitro transcription of the FRL7 and FRLP genes. The coding regions were amplified and tagged with the FLAG sequence (Hopp et al., 1986) at the C-terminus by PCR and inserted to pCSP+.
lmmunoblotting Anti-phosphotyrosine antibody 4G IO was purchased from Upstate Biotechnology, Incorporated. Anti-alkaline phosphatase was purchased from Medix Biotech. Anti-FLAG M2 antibody was purchased from Kodak. Polyclonal rabbit serum against FGF2 was raised against bacterially expressed Xenopus FGF2 protein (Kimelman et al., 1988) . For colony immunoblotting, we followed the procedure described by Lyons and Nelson (1984) . Colonies were transferred onto two nitrocellulose membranes (Millipore HATF 082) and incubated on SD and SG plates overnight at 30%. The cells were lysed with 0.1% SDS, 0.2 M NaOH, 35 mM DTT. Chemiluminescence reagents (ECL, Amersham) were used for detection.
cDNA Libraries Two cDNA libraries, the egg and embryo library and the XTC library, were used. The vector plasmid of the cDNA library was hYES (Elledge et al., 1991) .
cDNA for the XTC library was isolated from XTC cells and XTC cells treated with 100 nglml nocodazole for 24 hr. Untreated and nocodazole-treated mRNAs were used in the ratio 4:l. cDNA for the egg and embryo library was isolated from eggs, 10 hr embryos (gastrula), and 10 hr embryos treated with IO pglml nocodazole between 8 and IO hr. mRNA from each was used in the ratio 1:3:1. Assays Ca2+ Release Assay We followed the method previously described by Musci et al. (1990) and Amaya et al. (1991) . Injected oocytes were cultured at 16% for 48 hr and washed in Ca2+-free solution. %a*+ (Amersham) was loaded for 3 hr and then washed extensively.
The radioactivity released for the first 10 min was counted. in Vitro Binding Assay A DNA fragment encoding the extracellular domain of the FGF receptor (from Met-l to Glu-372) was fused to the human alkaline phosphatase gene (Flanagan and Leder, 1990) . COS cells were transiently transfected with the plasmid by the calcium phosphate method. The fusion protein was precipitated by anti-alkaline phosphatase antibody (Medix Biotech) and protein A-Sepharose (Pierce).
["Slmethionine-labeled FRLI and FRL2 proteins were synthesized in reticulocyte lysate with canine pancreatic microsomal membranes (Promega). PEtS (10 vol), 0.5% Triton X-100 was added and mixed to the receptor-clonjugated Sepharose described above. To test the competition with FGF for binding to the receptor, 1 pglml of bacterially produced Xenopus FGF2 protein was added. After overnight incubation at 4"C, 2 mM of DTSSP (Pierce) was added and incubated for 1 hr. The Sepharose beads were washed four times in TBS, 0.5% Triton X-100. Animal Cap Assay RNA was injected into both blastomeres at the 2-cell stage. Animal caps were isolated at stage 8 (Nieuwkoop and Faber, 1994) , incubated in 1 x MMR at 16OC until sibling embryos reached stage20, and then frozen for the RNA analysis. RT-PCR RT-PCR was carried out as described (Rupp and Weintraub, 1991; Wilson and Melton, 1994; Lustig and Kirschner, 1995) . The primer sequences used for analysis of EFl a, goosecoid, N-CAM, and muscle actin were as described (Hemmati-Erivanlou et al., 1994; HemmatiBrivanlou and Melton, 1994) . The primer sequences for FRLl are 5'-ATGCAGTTTTTAAGATTT-3'
and 5'-TTAAAGTCCAATATTCAG-3'. The sequences for FRLP are 5'-ATGCTTGACATTATGGTG-3' and 5'-TTATCTCATAGCAGGGAG-3'.
The sequences for ODC are 5'-AATG-GATTTCAGAGACCA-3' and S-CCAAGGCTAAAGTTGCAG3' (Bassez et al., 1990) . Paracrine Signaling Assay The paracrine signaling assay was carried out as described (Lustig and Kirschner, 1995) . Whole.Mount
In Situ Hybridization The procedure for the whole mount was carried out as described (Harland, 1991) . The antisense strands of the FRLI and FR1-2coding region were used for the probes.
